If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and ...

This is 40-something. Kim Kardashian, 45, has tried to cling to her youth by undergoing skin-tightening treatments, traveling ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Shopper News brings you the latest happenings in your community ...

From remote consultations to round-the-clock monitoring, these start-ups are pushing the limits of health care ...

Investing.com -- KeyBanc Capital Markets has identified three standout performers in the medical technology sector, with ...